Quick View
| Metric | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | - | - | - |
| Operating Income | −¥12.3B | −¥12.9B | +4.6% |
| Ordinary Income | −¥12.5B | −¥13.1B | +4.5% |
| Net Income | −¥12.5B | −¥13.1B | +4.5% |
| ROE (annualized) | −803.9% | −629.1% | - |
Executive Summary
For the nine months ended Q3 of FY2026, both the operating loss and net loss narrowed from the same period of the previous fiscal year. Although the scale of the losses remains significant, the results indicated an improving trend. The operating loss was ¥12.34B (¥12.93B in the previous year, an improvement of ¥0.59B), the ordinary loss was ¥12.46B (¥13.05B in the previous year), and the net loss was ¥12.48B (¥13.07B in the previous year, an improvement of ¥0.59B). Basic loss per share improved to ¥110.72 from ¥153.93 in the previous year. Despite the narrowing losses, cash and deposits decreased 29.0% from ¥3.39B at the end of the same period of the previous year to ¥2.41B, making the trend in funding capacity an ongoing area of focus.
Factors Affecting Performance
【Revenue】Revenue was not disclosed, and as a research and development-focused company, profit and loss is primarily determined by expense trends. Segment information was also not disclosed.
【Profit and Loss】The operating loss was ¥12.34B, an improvement of ¥0.59B (4.6%) year on year, while the ordinary loss also improved to ¥12.46B from ¥13.05B in the previous year. Non-operating income was ¥0.01B and non-operating expenses were ¥0.12B (including a foreign exchange loss of ¥0.05B), indicating a limited impact on ordinary income. Against a loss before income taxes of ¥12.46B, income taxes and other taxes of ¥0.02B were recorded, resulting in a net loss of ¥12.48B. Although the company remains in a loss-making, revenue-and-profit-decline structure, the loss margin narrowed from the previous year through expense management. Overall, the company is in a “loss-narrowing trend.”
Key Financial Indicators
【Profitability】Profit margins cannot be calculated because revenue was not disclosed; however, both the operating loss of ¥12.34B and the net loss of ¥12.48B narrowed year on year. ROE (annualized) was -803.9%, an extreme level reflecting the thin net asset base resulting from the expansion of accumulated losses.【Cash Quality】Cash and deposits were ¥2.41B, accounting for 73.8% of total assets of ¥326M, indicating that most assets consist of liquid assets.【Investment Efficiency】Fixed assets were small at ¥0.4B, and investment in property, plant and equipment was limited, with most capital held as cash and deposits.【Financial Soundness】The equity ratio was 62.9% (63.5% in the previous year), while both the current ratio and quick ratio were 240.8%, indicating that short-term payment capacity was secured. However, retained earnings had expanded to negative ¥111.79B, requiring continued monitoring of the impact of accumulated losses on the capital structure.
Cash Flow Analysis
Although a cash flow statement was not disclosed, funding trends can be identified from changes in the balance sheet. Cash and deposits decreased by ¥0.98B, or 29.0%, from ¥3.39B at the end of the same period of the previous year to ¥2.41B at the end of the current period, indicating continued cash consumption associated with the recording of losses. Total assets also contracted from ¥4.34B to ¥3.26B, while net assets declined from ¥2.77B to ¥2.07B. Cash and deposits of ¥2.41B still exceeded current liabilities of ¥1.20B, preserving short-term payment capacity; however, if the pace of decline in cash and deposits continues, it will be important to confirm the capacity for additional financing.
Earnings Quality
Most of the profit and loss arose from recurring business operating expenses, and no temporary factors corresponding to extraordinary gains or losses were identified. Non-operating income consisted of approximately ¥0.01B in interest income, compared with non-operating expenses of ¥0.12B (including a foreign exchange loss of ¥0.05B). The difference between the ordinary loss and operating loss was small, and the profit-and-loss structure was largely explained by operating results. Income taxes and other taxes of ¥0.02B were recorded against a loss before income taxes of ¥12.46B, indicating that a certain tax burden was incurred even during a loss-making period and causing the net loss to slightly exceed the loss before income taxes. As revenue was not disclosed, a precise accrual-based assessment is difficult; however, there was no significant divergence between the loss and the ¥0.98B decrease in cash and deposits, suggesting that most of the loss was substantive and accompanied by cash outflows.
Earnings Forecast and Guidance
The full-year company forecasts are an operating loss of ¥15.00B, an ordinary loss of ¥15.10B, and a net loss of ¥15.12B. The nine-month operating loss of ¥12.34B has reached 82.3% of the full-year forecast, while the net loss of ¥12.48B has reached 82.5%, both exceeding the standard progress rate of 75%. Based on these levels, achieving the full-year plan will require the standalone Q4 operating loss to be held to approximately ¥2.66B and the net loss to approximately ¥2.64B. Expense trends in the second half will therefore be key to achieving the plan.
Shareholder Returns
Both the Q2 dividend and the year-end dividend forecast are ¥0 per share, and the company continues to pay no dividends. With net losses continuing, the payout ratio is effectively 0%, and no share repurchase activity has been identified; therefore, the total return ratio cannot be calculated. With cash and deposits down 29.0% year on year, capital allocation is prioritizing research and development and business operating funds without paying dividends.
Risk Factors
-
Financing and Capital Depletion Risk: A nine-month net loss of ¥12.48B was recorded against net assets of ¥2.07B, while cash and deposits also declined 29.0% year on year. If losses continue, the need for additional financing or capital policy measures will increase.
-
Risk of Failure to Achieve the Full-Year Plan: Progress toward the full-year forecasts for both the operating loss and net loss has reached the 82% range, exceeding the standard progress rate of 75%. If Q4 losses cannot be contained in the ¥2.6B range, the company may exceed its full-year forecasts.
-
Pharmaceutical Development and Regulatory Risk: As a research and development-focused company, the progress of clinical trials, the timing of regulatory approvals, and changes to the pharmaceutical pricing system may affect the timing of future expense and revenue recognition. The sustainability of the loss-narrowing trend will depend on progress in these areas.
Industry Benchmark (Reference; Company Research)
No industry benchmark data available
Source: Company research
Key Takeaways from the Financial Results
-
Both the operating loss and net loss narrowed by ¥0.59B year on year, confirming improvement in expense management. However, the progress rate against the full-year forecasts was in the 82% range, making the level of the Q4 loss the key determinant of whether the full-year plan will be achieved.
-
Cash and deposits decreased 29.0% year on year to ¥2.41B. While short-term financial soundness was maintained, with a current ratio of 240.8% and an equity ratio of 62.9%, retained earnings had expanded to negative ¥111.79B, making the sustainability of the capital policy a medium- to long-term issue.
-
The company continues to pay no dividends, consistent with a policy of prioritizing the allocation of funds to research and development and business operations.
Theoretical Share Price (Reference Value)
| Scenario | Theoretical Share Price |
|---|---|
| bear (bearish) | ¥0 |
| base (baseline) | ¥0 |
| bull (bullish) | ¥0 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥17 |
| Adjusted Forecast EPS | -¥155.4 |
| Cost of Equity r | 10.87% (10-year Japanese government bond 2.87% + equity risk premium 6.00% + size premium 2.00%) |
| Residual Income Persistence Factor ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 30.0% |
| Forecast EPS Confidence Adjustment | ×1.000 (based on the track record of guidance achievement in the same industry) |
Sensitivity: -¥126 to -¥124 at ±1% in the cost of equity, and -¥125 to -¥125 at ±0.1 in ω.
Notes:
- Because forecast ROE is below the cost of equity, the theoretical value will be below book value per share.
- Net assets as of the quarter-end were used (there is a timing difference from the full-year forecast).
- Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.
(Calculation model: Residual Income Model (Ohlson type; explicit five-year fade) / Interest rate reference month: 2026-08 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and, where necessary, after consulting with a professional.
---End of Report---